Literature DB >> 29507851

Non-small Cell Lung Cancer with Multiple Brain Metastases Treated with Radiosurgery and Erlotinib: A Case Report.

Bilgehan Sahin1, Teuta Mustafayev2, Gokhan Aydin3, Gorkem Gungor2, Bulend Yapici2, Banu Atalar2, Enis Ozyar2.   

Abstract

Brain metastases are commonly seen complications in non-small cell lung cancer (NSCLC) patients. The incidence of brain metastases is increasing as a result of more effective systemic targeted therapies with prolonged survival. The prognosis is usually poor, and up to six months of median survivals were reported with different therapeutic options. Here, we present an NSCLC case with multiple brain metastases treated with radiosurgery and systemic erlotinib therapy with prolonged survival. The use of tyrosine kinase inhibitors (TKI) in conjunction with either stereotactic radiosurgery or whole brain radiotherapy is not well established in terms of efficiency and toxicity. This reported case had an excellent response with a tolerable toxicity profile from the combination of either therapies.

Entities:  

Keywords:  cyberknife radiosurgery; erlotinib; multiple brain metastases

Year:  2017        PMID: 29507851      PMCID: PMC5832407          DOI: 10.7759/cureus.2003

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  10 in total

Review 1.  The biology of brain metastases-translation to new therapies.

Authors:  April F Eichler; Euiheon Chung; David P Kodack; Jay S Loeffler; Dai Fukumura; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-04-12       Impact factor: 66.675

Review 2.  EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.

Authors:  Yu Yang Soon; Cheng Nang Leong; Wee Yao Koh; Ivan Weng Keong Tham
Journal:  Radiother Oncol       Date:  2015-01-09       Impact factor: 6.280

3.  Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.

Authors:  J B Sørensen; H H Hansen; M Hansen; P Dombernowsky
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

4.  Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

Authors:  William J Magnuson; Nataniel H Lester-Coll; Abraham J Wu; T Jonathan Yang; Natalie A Lockney; Naamit K Gerber; Kathryn Beal; Arya Amini; Tejas Patil; Brian D Kavanagh; D Ross Camidge; Steven E Braunstein; Lauren C Boreta; Suresh K Balasubramanian; Manmeet S Ahluwalia; Niteshkumar G Rana; Albert Attia; Scott N Gettinger; Joseph N Contessa; James B Yu; Veronica L Chiang
Journal:  J Clin Oncol       Date:  2017-01-23       Impact factor: 44.544

Review 5.  The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Laurie E Gaspar; Minesh P Mehta; Roy A Patchell; Stuart H Burri; Paula D Robinson; Rachel E Morris; Mario Ammirati; David W Andrews; Anthony L Asher; Charles S Cobbs; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Michael McDermott; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Timothy C Ryken; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

6.  A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.

Authors:  Paul W Sperduto; Meihua Wang; H Ian Robins; Michael C Schell; Maria Werner-Wasik; Ritsuko Komaki; Luis Souhami; Mark K Buyyounouski; Deepak Khuntia; William Demas; Sunjay A Shah; Lucien A Nedzi; Gad Perry; John H Suh; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-04       Impact factor: 7.038

Review 7.  The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma.

Authors:  Hongqing Zhuang; Jun Wang; Lujun Zhao; Zhiyong Yuan; Ping Wang
Journal:  Int J Cancer       Date:  2013-06-21       Impact factor: 7.396

8.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.

Authors:  Masaaki Yamamoto; Toru Serizawa; Takashi Shuto; Atsuya Akabane; Yoshinori Higuchi; Jun Kawagishi; Kazuhiro Yamanaka; Yasunori Sato; Hidefumi Jokura; Shoji Yomo; Osamu Nagano; Hiroyuki Kenai; Akihito Moriki; Satoshi Suzuki; Yoshihisa Kida; Yoshiyasu Iwai; Motohiro Hayashi; Hiroaki Onishi; Masazumi Gondo; Mitsuya Sato; Tomohide Akimitsu; Kenji Kubo; Yasuhiro Kikuchi; Toru Shibasaki; Tomoaki Goto; Masami Takanashi; Yoshimasa Mori; Kintomo Takakura; Naokatsu Saeki; Etsuo Kunieda; Hidefumi Aoyama; Suketaka Momoshima; Kazuhiro Tsuchiya
Journal:  Lancet Oncol       Date:  2014-03-10       Impact factor: 41.316

9.  Prognosis of patients treated for intracranial metastases with whole-brain irradiation.

Authors:  J T Sundström; H Minn; K K Lertola; E Nordman
Journal:  Ann Med       Date:  1998-06       Impact factor: 4.709

10.  The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.

Authors:  Hao Bai; Liwen Xiong; Baohui Han
Journal:  Onco Targets Ther       Date:  2017-04-27       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.